openPR Logo
Press release

Investigation announced for Investors in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares

08-23-2021 06:58 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares over potential securities laws violations.

An investigation for investors in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares over potential securities laws violations.

Rigel Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Rigel Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Francisco, CA based Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.

On August 13, 2021, Rigel Pharmaceuticals, Inc. issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 are insufficient for an emergency use authorization (EUA) at this time."

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) declined from $4.62 per share on June 28, 2021, to $3.44 per share on August 13, 2021.

Those who purchased shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares here

News-ID: 2364318 • Views:

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, Inc. (NYSE: DV)
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Rigel

Aerosol Photometer Market | Air Techniques, Norda-China, Qingdao Zhongrui, Rigel
The global aerosol photometer market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the aerosol photometer market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth of the
Ventilation Tester Market Demand and Supply Analysis, Excellent Growth & Forecas …
Ventilation Tester Market 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝟐𝟎𝟐𝟐 𝐢𝐬 𝐜𝐚𝐫𝐞𝐟𝐮𝐥𝐥𝐲 𝐜𝐨𝐧𝐝𝐮𝐜𝐭𝐞𝐝 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐢𝐧 𝐚 𝐪𝐮𝐚𝐥𝐢𝐭𝐚𝐭𝐢𝐯𝐞 𝐚𝐧𝐝 𝐜𝐨𝐧𝐬𝐢𝐬𝐭𝐞𝐧𝐭 𝐰𝐚𝐲 𝐭𝐨 𝐞𝐧𝐬𝐮𝐫𝐞 𝐚 𝐬𝐮𝐜𝐜𝐞𝐬𝐬𝐟𝐮𝐥 𝐨𝐮𝐭𝐜𝐨𝐦𝐞 of the Ventilation Tester Market. In addition to identifying, analyzing, and estimating new trends, this research report also examines key industry drivers, challenges, and opportunities in addition to evaluating competitors, geographical areas, types, and applications. Understanding the competitive landscape is crucial for determining the product improvements that
Electrosurgical Analyzer Market 2022 Insights: Fluke Biomedical, Rigel Medical, …
Electrosurgical Analyzer Market research report deals with many parameters in depth to satisfy the requirements of business or clients. Moreover, it also displays all the information including market definition, classifications, key developments, applications, and engagements along with the detailed actions of key players with respect to product launches, joint ventures, developments, mergers and acquisitions, and effects of the same in terms of sales, import, export, revenue and CAGR values. A
Investigation announced for Long-Term Investors in shares of Rigel Pharmaceutica …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Rigel Pharmaceuticals, Inc. Investors who purchased shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Rigel Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders. San Francisco,
Pressure Tester Market Trend, SWOT Analysis, Opportunity Assessments 2021-2027 | …
"The report titled Global Pressure Tester Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Pressure Tester market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Pressure Tester market. Market
Rigel Networks Is Now A Kentico Certified Silver Partner
9th July 2019, Vadodara, Gujarat — Rigel Networks, an End to End IT Service Provider Company, today announced it has entered a Silver Partnership with Kentico Software (https://www.kentico.com), the Web Content and Customer Experience Management Provider, to provide customers with conversion-oriented web development solutions. From catering IT Services, Blockchain, Staffing, and VoIP, Rigel Networks delivers innovative technology-based IT services and solutions to their global clients for diverse industries to meet their